Equities

SymBio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)252.00
  • Today's Change4.00 / 1.61%
  • Shares traded776.70k
  • 1 Year change-32.44%
  • Beta0.7583
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6,5176,2833,860
Total Receivables, Net9132,0852,148
Total Inventory232469386
Prepaid expenses391463338
Other current assets, total301317
Total current assets8,0839,3136,748
Property, plant & equipment, net06984
Goodwill, net------
Intangibles, net0222259
Long term investments----0
Note receivable - long term------
Other long term assets888587
Total assets8,17010,4338,453
LIABILITIES
Accounts payable04770
Accrued expenses----516
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total9571,877932
Total current liabilities9571,9241,518
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total3.713.39189
Total liabilities9601,9271,707
SHAREHOLDERS EQUITY
Common stock17,95317,54817,158
Additional paid-in capital17,92817,52317,133
Retained earnings (accumulated deficit)(28575)(26478)(27458)
Treasury stock - common(89)(88)(86)
Unrealized gain (loss)------
Other equity, total(5.99)0.240.00
Total equity7,2108,5066,746
Total liabilities & shareholders' equity8,17010,4338,453
Total common shares outstanding424038
Treasury shares - common primary issue0.090.090.08
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.